Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
1702 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Breast Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Breast Cancer - Pipeline Review, H2 2014', provides an overview of the Breast Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Breast Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 14 Breast Cancer Overview 15 Therapeutics Development 16 Breast Cancer - Therapeutics under Development by Companies 18 Breast Cancer - Therapeutics under Investigation by Universities/Institutes 44 Breast Cancer - Pipeline Products Glance 51 Breast Cancer - Products under Development by Companies 55 Breast Cancer - Products under Investigation by Universities/Institutes 89 Breast Cancer - Companies Involved in Therapeutics Development 98 Breast Cancer - Therapeutics Assessment 394 Drug Profiles 429 Breast Cancer - Recent Pipeline Updates 1305 Breast Cancer - Dormant Projects 1589 Breast Cancer - Discontinued Products 1617 Breast Cancer - Product Development Milestones 1623 Appendix 1633
List of Tables Number of Products under Development for Breast Cancer, H2 2014 84 Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2014 85 Number of Products under Development by Companies, H2 2014 87 Number of Products under Development by Companies, H2 2014 (Contd..1) 88 Number of Products under Development by Companies, H2 2014 (Contd..2) 89 Number of Products under Development by Companies, H2 2014 (Contd..3) 90 Number of Products under Development by Companies, H2 2014 (Contd..4) 91 Number of Products under Development by Companies, H2 2014 (Contd..5) 92 Number of Products under Development by Companies, H2 2014 (Contd..6) 93 Number of Products under Development by Companies, H2 2014 (Contd..7) 94 Number of Products under Development by Companies, H2 2014 (Contd..8) 95 Number of Products under Development by Companies, H2 2014 (Contd..9) 96 Number of Products under Development by Companies, H2 2014 (Contd..10) 97 Number of Products under Development by Companies, H2 2014 (Contd..11) 98 Number of Products under Development by Companies, H2 2014 (Contd..12) 99 Number of Products under Development by Companies, H2 2014 (Contd..13) 100 Number of Products under Development by Companies, H2 2014 (Contd..14) 101 Number of Products under Development by Companies, H2 2014 (Contd..15) 102 Number of Products under Development by Companies, H2 2014 (Contd..16) 103 Number of Products under Development by Companies, H2 2014 (Contd..17) 104 Number of Products under Development by Companies, H2 2014 (Contd..18) 105 Number of Products under Development by Companies, H2 2014 (Contd..19) 106 Number of Products under Development by Companies, H2 2014 (Contd..20) 107 Number of Products under Development by Companies, H2 2014 (Contd..21) 108 Number of Products under Development by Companies, H2 2014 (Contd..22) 109 Number of Products under Development by Companies, H2 2014 (Contd..23) 110 Number of Products under Development by Companies, H2 2014 (Contd..24) 111 Number of Products under Investigation by Universities/Institutes, H2 2014 113 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 114 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 115 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..3) 116 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..4) 117 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..5) 118 Comparative Analysis by Late Stage Development, H2 2014 119 Comparative Analysis by Clinical Stage Development, H2 2014 120 Comparative Analysis by Early Stage Development, H2 2014 121 Comparative Analysis by Unknown Stage Development, H2 2014 122 Products under Development by Companies, H2 2014 123 Products under Development by Companies, H2 2014 (Contd..1) 124 Products under Development by Companies, H2 2014 (Contd..2) 125 Products under Development by Companies, H2 2014 (Contd..3) 126 Products under Development by Companies, H2 2014 (Contd..4) 127 Products under Development by Companies, H2 2014 (Contd..5) 128 Products under Development by Companies, H2 2014 (Contd..6) 129 Products under Development by Companies, H2 2014 (Contd..7) 130 Products under Development by Companies, H2 2014 (Contd..8) 131 Products under Development by Companies, H2 2014 (Contd..9) 132 Products under Development by Companies, H2 2014 (Contd..10) 133 Products under Development by Companies, H2 2014 (Contd..11) 134 Products under Development by Companies, H2 2014 (Contd..12) 135 Products under Development by Companies, H2 2014 (Contd..13) 136 Products under Development by Companies, H2 2014 (Contd..14) 137 Products under Development by Companies, H2 2014 (Contd..15) 138 Products under Development by Companies, H2 2014 (Contd..16) 139 Products under Development by Companies, H2 2014 (Contd..17) 140 Products under Development by Companies, H2 2014 (Contd..18) 141 Products under Development by Companies, H2 2014 (Contd..19) 142 Products under Development by Companies, H2 2014 (Contd..20) 143 Products under Development by Companies, H2 2014 (Contd..21) 144 Products under Development by Companies, H2 2014 (Contd..22) 145 Products under Development by Companies, H2 2014 (Contd..23) 146 Products under Development by Companies, H2 2014 (Contd..24) 147 Products under Development by Companies, H2 2014 (Contd..25) 148 Products under Development by Companies, H2 2014 (Contd..26) 149 Products under Development by Companies, H2 2014 (Contd..27) 150 Products under Development by Companies, H2 2014 (Contd..28) 151 Products under Development by Companies, H2 2014 (Contd..29) 152 Products under Development by Companies, H2 2014 (Contd..30) 153 Products under Development by Companies, H2 2014 (Contd..31) 154 Products under Development by Companies, H2 2014 (Contd..32) 155 Products under Development by Companies, H2 2014 (Contd..33) 156 Products under Investigation by Universities/Institutes, H2 2014 157 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 158 Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 159 Products under Investigation by Universities/Institutes, H2 2014 (Contd..3) 160 Products under Investigation by Universities/Institutes, H2 2014 (Contd..4) 161 Products under Investigation by Universities/Institutes, H2 2014 (Contd..5) 162 Products under Investigation by Universities/Institutes, H2 2014 (Contd..6) 163 Products under Investigation by Universities/Institutes, H2 2014 (Contd..7) 164 Products under Investigation by Universities/Institutes, H2 2014 (Contd..8) 165 Breast Cancer - Pipeline by 3-V Biosciences, Inc., H2 2014 166 Breast Cancer - Pipeline by A&G Pharmaceutical, Inc., H2 2014 167 Breast Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 168 Breast Cancer - Pipeline by AB Science, H2 2014 169 Breast Cancer - Pipeline by AbbVie Inc., H2 2014 170 Breast Cancer - Pipeline by AbGenomics International, Inc., H2 2014 171 Breast Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 172 Breast Cancer - Pipeline by Adaptimmune Limited, H2 2014 173 Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2014 174 Breast Cancer - Pipeline by Advaxis, Inc., H2 2014 175 Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2014 176 Breast Cancer - Pipeline by Aegis Therapeutics, LLC, H2 2014 177 Breast Cancer - Pipeline by Aerpio Therapeutics, Inc., H2 2014 178 Breast Cancer - Pipeline by Aeterna Zentaris Inc., H2 2014 179 Breast Cancer - Pipeline by Affichem, H2 2014 180 Breast Cancer - Pipeline by Aileron Therapeutics, Inc., H2 2014 181 Breast Cancer - Pipeline by Alchemia Limited, H2 2014 182 Breast Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2014 183 Breast Cancer - Pipeline by Almac Discovery Ltd., H2 2014 184 Breast Cancer - Pipeline by AlphaMab Co., Ltd, H2 2014 185 Breast Cancer - Pipeline by Alteogen Inc., H2 2014 186 Breast Cancer - Pipeline by Ambrx, Inc., H2 2014 187 Breast Cancer - Pipeline by Amgen Inc., H2 2014 188 Breast Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H2 2014 189 Breast Cancer - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2014 190 Breast Cancer - Pipeline by Angion Biomedica Corp., H2 2014 191 Breast Cancer - Pipeline by AntiCancer, Inc., H2 2014 192 Breast Cancer - Pipeline by Antigen Express, Inc., H2 2014 193 Breast Cancer - Pipeline by Antoxis Limited, H2 2014 194 Breast Cancer - Pipeline by Aphios Corporation, H2 2014 195 Breast Cancer - Pipeline by Aptose Biosciences Inc., H2 2014 196 Breast Cancer - Pipeline by Armour Therapeutics Inc., H2 2014 197 Breast Cancer - Pipeline by Arno Therapeutics, Inc., H2 2014 198 Breast Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2014 199 Breast Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2014 200 Breast Cancer - Pipeline by Ascentage Pharma Group Corporation, Ltd., H2 2014 201 Breast Cancer - Pipeline by AstraZeneca PLC, H2 2014 202 Breast Cancer - Pipeline by Aurigene Discovery Technologies Limited, H2 2014 203 Breast Cancer - Pipeline by Avipep Pty Ltd, H2 2014 204 Breast Cancer - Pipeline by Axelar AB, H2 2014 205 Breast Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014 206 Breast Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2014 207 Breast Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 208 Breast Cancer - Pipeline by Bayer AG, H2 2014 209 Breast Cancer - Pipeline by BBB Therapeutics B.V., H2 2014 210 Breast Cancer - Pipeline by BerGenBio AS, H2 2014 211 Breast Cancer - Pipeline by BHR Pharma, LLC, H2 2014 212 Breast Cancer - Pipeline by Bio-Path Holdings, Inc., H2 2014 213 Breast Cancer - Pipeline by Bionomics Limited, H2 2014 214 Breast Cancer - Pipeline by BioNTech AG, H2 2014 215 Breast Cancer - Pipeline by Bioo Therapeutics, H2 2014 216 Breast Cancer - Pipeline by BiOrion Technologies B.V., H2 2014 217 Breast Cancer - Pipeline by Biotecnol, Inc., H2 2014 218 Breast Cancer - Pipeline by Biotest AG, H2 2014 219 Breast Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2014 220 Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 221 Breast Cancer - Pipeline by Boston Biomedical, Inc., H2 2014 222 Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 223 Breast Cancer - Pipeline by Calithera Biosciences, Inc., H2 2014 224 Breast Cancer - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2014 225 Breast Cancer - Pipeline by Cavion LLC, H2 2014 226 Breast Cancer - Pipeline by CEL-SCI Corporation, H2 2014 227 Breast Cancer - Pipeline by Celgene Corporation, H2 2014 228 Breast Cancer - Pipeline by Cellceutix Corporation, H2 2014 229 Breast Cancer - Pipeline by Celltrion, Inc., H2 2014 230 Breast Cancer - Pipeline by Celsion Corporation, H2 2014 231 Breast Cancer - Pipeline by Cerulean Pharma, Inc., H2 2014 232 Breast Cancer - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute, H2 2014 233 Breast Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2014 234 Breast Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 235 Breast Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 236 Breast Cancer - Pipeline by CIMAB S.A., H2 2014 237 Breast Cancer - Pipeline by Clovis Oncology, Inc., H2 2014 238 Breast Cancer - Pipeline by Cold Genesys, Inc., H2 2014 239 Breast Cancer - Pipeline by Compugen Ltd., H2 2014 240 Breast Cancer - Pipeline by Coronado Biosciences, Inc., H2 2014 241 Breast Cancer - Pipeline by Covagen AG, H2 2014 242 Breast Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2014 243 Breast Cancer - Pipeline by Curadev Pharma Private Limited, H2 2014 244 Breast Cancer - Pipeline by Curaxys, S.L., H2 2014 245 Breast Cancer - Pipeline by CureFAKtor Pharmaceuticals. LLC, H2 2014 246 Breast Cancer - Pipeline by Curis, Inc., H2 2014 247 Breast Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2014 248 Breast Cancer - Pipeline by CytomX Therapeutics, Inc., H2 2014 249 Breast Cancer - Pipeline by CZ BioMed Corp, H2 2014 250 Breast Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 251 Breast Cancer - Pipeline by Debiopharm International S.A., H2 2014 252 Breast Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 253 Breast Cancer - Pipeline by Dendreon Corporation, H2 2014 254 Breast Cancer - Pipeline by DexTech Medical AB, H2 2014 255 Breast Cancer - Pipeline by Digna Biotech, S.L., H2 2014 256 Breast Cancer - Pipeline by DiNonA Inc., H2 2014 257 Breast Cancer - Pipeline by Dong-A Socio Group, H2 2014 258 Breast Cancer - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2014 259
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
